0001564590-21-045178.txt : 20210819 0001564590-21-045178.hdr.sgml : 20210819 20210819160602 ACCESSION NUMBER: 0001564590-21-045178 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210818 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210819 DATE AS OF CHANGE: 20210819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HTG MOLECULAR DIAGNOSTICS, INC CENTRAL INDEX KEY: 0001169987 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 860912294 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37369 FILM NUMBER: 211190159 BUSINESS ADDRESS: STREET 1: 3430 E. GLOBAL LOOP CITY: TUCSON STATE: AZ ZIP: 85706 BUSINESS PHONE: 877-289-2615 MAIL ADDRESS: STREET 1: 3430 E. GLOBAL LOOP CITY: TUCSON STATE: AZ ZIP: 85706 FORMER COMPANY: FORMER CONFORMED NAME: HTG MOLECULAR DIAGNOSTICS INC DATE OF NAME CHANGE: 20110523 FORMER COMPANY: FORMER CONFORMED NAME: HIGH THROUGHPUT GENOMICS INC DATE OF NAME CHANGE: 20020326 8-K 1 htgm-8k_20210818.htm HTGM-8K-2021-08-18 htgm-8k_20210818.htm
false 0001169987 0001169987 2021-08-18 2021-08-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 18, 2021

Date of Report (Date of earliest event reported)

 

HTG Molecular Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-37369

 

86-0912294

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3430 E. Global Loop

Tucson, AZ

 

85706

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (877) 289-2615

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

 

HTGM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e)

 

As described under Item 5.07 of this report, at the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of HTG Molecular Diagnostics, Inc. (the “Company”) held on August 18, 2021, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved, along with other items discussed in Item 5.07 below, the HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan (the “Amended 2014 ESPP”), which amends and restates the HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan (the “2014 ESPP”) and is the successor to and replacement of the 2014 ESPP. The Amended 2014 ESPP became effective on August 18, 2021 upon the approval of the stockholders at the Annual Meeting. A description of the Amended 2014 ESPP is set forth under the heading “Summary of the Amended 2014 ESPP” contained in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on July 7, 2021 (the “Proxy Statement”). Such description is incorporated by reference herein. Such description is only a summary and is qualified in its entirety by reference to the complete text of the Amended 2014 ESPP, a copy of which is filed as Exhibit 10.1 to this report.  

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes with respect to each matter. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

Proposal 1. Election of Directors

The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Votes For

 

 

Votes
Withheld

 

 

Broker
Non-Votes

 

Ann F. Hanham, Ph.D.

 

1,843,121

 

 

 

148,446

 

 

 

2,378,780

 

 

Michelle R. Griffin

 

1,862,730

 

 

 

128,837

 

 

 

2,378,780

 

 

Proposal 2. Approval of the Amended 2014 ESPP

 

The Company’s stockholders approved the adoption of the Amended 2014 ESPP. The final voting results are as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker
Non-Votes

1,899,249

 

36,813

 

55,505

 

2,378,780

Proposal 3. Approval of the Authorization to Adjourn the Annual Meeting

 

The Company’s stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 2. The final voting results are as follows:

 

Votes For

 

Votes Against

 

Abstentions

 

Broker

Non-Votes

1,868,179

 

71,128

 

52,260

 

2,378,780

 

 

 

 

 

 

Proposal 4. Advisory Approval of the Compensation of the Company’s Named Executive Officers

 

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The final voting results are as follows:

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker

Non-Votes

1,860,813

 

71,114

 

59,640

 

2,378,780

Proposal 5. Advisory Indication of the Preferred Frequency of Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers

 

The Company’s stockholders indicated their preference regarding how frequently the Company should solicit a non-binding advisory vote on the compensation of the Company’s named executive officers. The final voting results are as follows:

 

One Year

 

Two Years

 

Three Years

 

Abstentions

 

Broker

Non-Votes

1,879,238

 

9,836

 

31,039

 

71,454

 

2,378,780

In light of this result, the Company has determined to hold future advisory votes on executive compensation every year until the next required vote on the frequency of stockholder advisory votes on executive compensation.

Proposal 6. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Board of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results are as follows:

Votes For

 

Votes Against

 

Abstentions

 

Broker

Non-Votes

4,220,173

 

99,373

 

50,801

 

0

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

Exhibit

No.

 

Description

 

 

 

10.1

 

HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan

104

 

The cover page of this report has been formatted in Inline XBRL.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

HTG Molecular Diagnostics, Inc.

 

 

 

 

 

Dated: August 19, 2021

 

By:

 

/s/ Shaun D. McMeans

 

 

 

 

Shaun D. McMeans

 

 

 

 

SVP and Chief Financial Officer

 

 

 EX-10.1 2 htgm-ex101_24.htm EX-10.1 htgm-ex101_24.htm

Exhibit 10.1

HTG Molecular Diagnostics, Inc.

Amended and Restated 2014 Employee Stock Purchase Plan

Adopted by the Board of Directors: May 20, 2021

Approved by the Stockholders: August 18, 2021

1.General; Purpose.

(a)The Plan is adopted by the Company as the successor to and replacement of the HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan (the “Prior Plan”).  Effective as of the approval of the Plan by the stockholders of the Company (the “Effective Date”), the Prior Plan shall be terminated. Notwithstanding the foregoing, ongoing Offerings under the Prior Plan on the Effective Date will continue.

(b)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock.  The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan.

(c)The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.

2.Administration.

(a)The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b)The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i)To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).

(ii)To designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan.

(iii)To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.

(iv)To settle all controversies regarding the Plan and Purchase Rights granted under the Plan.

(v)To suspend or terminate the Plan at any time as provided in Section 12.

 

 

 

 

(vi)To amend the Plan at any time as provided in Section 12.

(vii)Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.

(viii)To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.

(c)The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.  Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.

(d)All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

3.Shares of Common Stock Subject to the Plan.

(a)Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 524,285 shares of Common Stock, which is the sum of (i) 24,285 shares that were available under the Prior Plan as of June 22, 2021 and (ii) an additional 500,000 shares that were approved by our stockholders at the 2021 Annual Meeting of Stockholders.  

(b)If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.  

(c)The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.  

4.Grant of Purchase Rights; Offering.

(a)The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board.  Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and will comply with

2

 

 

the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges.  The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan.  The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.

(b)If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.

(c)The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.  

5.Eligibility.

(a)Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation.  Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years.  In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.

(b)The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering.  Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:

(i)the date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right;

3

 

 

(ii)the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and

(iii)the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering.

(c)No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation.  For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.

(d)As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.

(e)Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan.  Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.

6.Purchase Rights; Purchase Price.

(a)On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee’s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.

(b)The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering.

(c)In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any

4

 

 

Purchase Date under the Offering.  If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable.

(d)The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of:

(i)an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or

(ii)an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.

7.Participation; Withdrawal; Termination.

(a)An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior  Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering).  If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions.  If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date.

(b)During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a withdrawal form provided by the Company.  The Company may impose a deadline before a Purchase Date for withdrawing.  Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately terminate and the Company will distribute to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering shall thereupon terminate.  A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings.

(c)Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company will distribute to such individual all of his or her accumulated but unused Contributions.

5

 

 

(d)During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant.  Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10.  

(e)Unless otherwise specified in the Offering, the Company will have no obligation to pay interest on Contributions.

8.Exercise of Purchase Rights.

(a)On each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering.  No fractional shares will be issued unless specifically provided for in the Offering.

(b)If any amount of accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant’s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date, without interest.  If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest.

(c)No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan.  If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date.  If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.

9.Covenants of the Company.

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder.  If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company

6

 

 

deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights.

10.Designation of Beneficiary.

(a)The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant.  The Company may, but is not obligated to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company.

(b)  If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant.  If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

11.Adjustments upon Changes in Common Stock; Corporate Transactions.

(a)In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iii) the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering.  The Board will make these adjustments, and its determination will be final, binding and conclusive.

(b)In the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common Stock within ten business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.

12.Amendment, Termination or Suspension of the Plan.

(a)The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.  However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements, including any

7

 

 

amendment that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible to become Participants and receive Purchase Rights, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv) materially extends the term of the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or listing requirements.

(b)The Board may suspend or terminate the Plan at any time.  No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.

(c)Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment.  To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423 of the Code.

13.Effective Date of Plan.

The Plan will become effective on the date the Plan is approved by the stockholders of the Company.  No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board.

14.Miscellaneous Provisions.

(a)Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.

(b)A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).

(c)The Plan and Offering do not constitute an employment contract.  Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or  be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.

8

 

 

(d)The provisions of the Plan will be governed by the laws of the State of Arizona without resort to that state’s conflicts of laws rules.

15.Definitions.

As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

(a)“Board” means the Board of Directors of the Company.

(b)“Capital Stock” means each and every class of common stock of the Company, regardless of the number of votes per share.

(c)“Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(d)“Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

(e)“Committee” means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).

(f)“Common Stock” means the common stock of the Company, having 1 vote per share.

(g)“Company” means HTG Molecular Diagnostics, Inc., a Delaware corporation.

(h)“Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.

(i)“Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i)a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;

9

 

 

(ii)a sale or other disposition of at least 50% of the outstanding securities of the Company;

(iii)a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

(iv)a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

(j)“Director” means a member of the Board.

(k)“Eligible Employee” means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.

(l)“Employee” means any person, including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.  

(m)“Employee Stock Purchase Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code.

(n)“Exchange Act” means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.

(o)“Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i)If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable.  Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.

(ii)In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code.

(p)  “Offering” means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase

10

 

 

Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for that Offering.

(q)“Offering Date” means a date selected by the Board for an Offering to commence.

(r)“Officer” means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.

(s)“Participant” means an Eligible Employee who holds an outstanding Purchase Right.

(t)“Plan” means this HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan.

(u)“Purchase Date” means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.

(v)“Purchase Period” means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date.  An Offering may consist of one or more Purchase Periods.

(w)“Purchase Right” means an option to purchase shares of Common Stock granted pursuant to the Plan.

(x)“Related Corporation” means any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

(y)“Securities Act” means the Securities Act of 1933, as amended.

(z)“Trading Day” means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading.

11

 

 EX-101.SCH 3 htgm-20210818.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 htgm-20210818_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 htgm-20210818_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 htgm-8k_20210818_htm.xml IDEA: XBRL DOCUMENT 0001169987 2021-08-18 2021-08-18 false 0001169987 8-K 2021-08-18 HTG Molecular Diagnostics, Inc. DE 001-37369 86-0912294 3430 E. Global Loop Tucson AZ 85706 877 289-2615 false false false false Common Stock, $0.001 par value per share HTGM NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 18, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 18, 2021
Entity Registrant Name HTG Molecular Diagnostics, Inc.
Entity Central Index Key 0001169987
Entity Emerging Growth Company false
Entity File Number 001-37369
Entity Tax Identification Number 86-0912294
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3430 E. Global Loop
Entity Address, City or Town Tucson
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85706
City Area Code 877
Local Phone Number 289-2615
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol HTGM
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports htgm-8k_20210818.htm htgm-20210818.xsd htgm-20210818_lab.xml htgm-20210818_pre.xml htgm-ex101_24.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "htgm-8k_20210818.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "htgm-8k_20210818.htm" ] }, "labelLink": { "local": [ "htgm-20210818_lab.xml" ] }, "presentationLink": { "local": [ "htgm-20210818_pre.xml" ] }, "schema": { "local": [ "htgm-20210818.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "htgm", "nsuri": "http://www.htgmolecular.com/20210818", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "htgm-8k_20210818.htm", "contextRef": "C_0001169987_20210818_20210818", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "htgm-8k_20210818.htm", "contextRef": "C_0001169987_20210818_20210818", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.htgmolecular.com/20210818/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-21-045178-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-045178-xbrl.zip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end